King International Investment Limited (HKG:0928)
0.0790
+0.0050 (6.76%)
Jun 6, 2025, 3:21 PM HKT
HKG:0928 Revenue
King International Investment had revenue of 37.19M HKD in the half year ending September 30, 2024, a decrease of -34.08%. This brings the company's revenue in the last twelve months to 187.44M, down -25.28% year-over-year. In the fiscal year ending March 31, 2024, King International Investment had annual revenue of 233.68M with 4.39% growth.
Revenue (ttm)
187.44M
Revenue Growth
-25.28%
P/S Ratio
0.78
Revenue / Employee
14.42M
Employees
13
Market Cap
146.18M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2024 | 233.68M | 9.83M | 4.39% |
Mar 31, 2023 | 223.85M | 130.98M | 141.03% |
Mar 31, 2022 | 92.87M | -9.17M | -8.98% |
Mar 31, 2021 | 102.04M | 38.24M | 59.93% |
Mar 31, 2020 | 63.81M | 318.00K | 0.50% |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
BeOne Medicines | 32.53B |
Hansoh Pharmaceutical Group Company | 13.05B |
JD Health International | 61.89B |
Innovent Biologics | 10.03B |
CSPC Pharmaceutical Group | 28.99B |
WuXi Biologics | 19.87B |
Sino Biopharmaceutical | 30.72B |
Sichuan Kelun-Biotech Biopharmaceutical | 2.06B |